[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"elderly-adults\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:elderly-adults":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100263018","phase-4-sleep-apnea-in-elderly-100263018",false,"NCT02703220","Sleep Apnea in Elderly","Pathophysiology-Guided Therapy for Sleep Apnea in the Elderly","Inclusion Criteria:\n\n* Adults with mild to moderate sleep apnea with Apnea-Hypopnea Index (AHI)\\>\u002F=5 to 20\u002Fhour with central, obstructive, mixed apneas and hypopneas\n* For the finasteride protocol elderly men with above criteria will be enrolled\n\nExclusion Criteria:\n\n* Patients with severe sleep apnea (Apnea-Hypopnea Index (AHI)\\>20\u002Fhour)\n* Patients with history of prostate cancer\n* Males with hypogonadism\n* History of cardiac disease, including myocardial infarction\n* Bypass surgery\n* Atrial and ventricular tachy-bradycardias\n* Systolic congestive heart failure and Cheyne-Stokes respiration\n* Current unstable angina\n* Stroke\n* Schizophrenia\n* Untreated hypothyroidism\n* Seizure disorder\n* Preexisting renal failure and liver disorders\n* Failure to give informed consent.\n* Patients with significant pulmonary diseases by history and abnormal pulmonary function testing, including moderate obstructive\u002Frestrictive lung\u002Fchest wall disorders with resting oxygen saturation of \\\u003C96% or on supplemental oxygen\n* Patients on certain medications including:\n\n  * study drugs\n  * sympathomimetics\u002Fparasympathomimetics or their respective blockers\n  * narcotics\n  * antidepressants\n  * anti-psychotic agents\n  * other central nervous system (CNS) altering medications\n  * current alcohol, tobacco or recreational drug use\n* Patients with Body mass index (BMI)\\>34 kilograms per square meter (kg\u002Fm2) will be excluded to avoid the effects of morbid obesity on pulmonary mechanics and ventilatory control\n* Elderly with unstable gait or mobility issues that may preclude safe participation\n* Individuals with allergy to finasteride or acetazolamide will be excluded from the specific protocol\n* Pregnant women",true,"ALL","60 Years","89 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Sleep-disordered breathing (SDB or sleep apnea) is very common among elderly Veterans and leads to increased morbidity and mortality in this population. The proposal aims to identity whether oxygen, finasteride and acetazolamide can be effective in reducing unstable breathing and eliminating sleep apnea in the elderly via different mechanisms. This proposal will enhance the investigators' understanding of the pathways that contribute to the development of sleep apnea in the elderly. The investigators expect that the results obtained from this study will positively impact the health of Veterans by identifying new treatment modalities for sleep apnea. A cumulative effect of the investigators' research will fulfill the long-term goal of improving the quality of life of elderly Veterans suffering from sleep apnea and its potential life-threatening complications.",[28,29],"Sleep Apnea","Elderly Adults",[31,32,33,34,35,36,37,38],"sleep apnea","chemoresponsiveness","cerebrovascular response","hyperoxia","acetazolamide","finasteride","apneic threshold","carbon-dioxide reserve","RECRUITING","2026-08-19",{"date":42,"type":43},"2026-08-21","ACTUAL",{"date":45,"type":43},"2015-07-03",{"date":47,"type":22},"2027-12-31",{"name":49,"class":50},"VA Office of Research and Development","FED",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100650328","cognitive-intervention-for-cognitive-impairment-100650328","NCT07747675","Cognitive Intervention for Cognitive Impairment","Cognitive Intervention to Improve Mild Cognitive Impairment in Older Adults: Randomized Double-blind Clinical Trial","Inclusion Criteria:\n\n* Affiliation with IMSS Aguascalientes Family Medicine Unit (UMF) No. 7; age 65 to 95 years; male or female; known diagnosis of type 2 diabetes mellitus; any level of education; any occupation; presence of mild cognitive impairment; availability to attend cognitive intervention sessions; and signing of informed consent.\n\nExclusion Criteria:\n\n* Patients with disabling hearing and\u002For visual impairments, patients with paralysis, and patients with severe psychiatric illness.","65 Years","95 Years",{"count":62,"type":22},102,[64],"NA","Mild cognitive impairment is characterized by cognitive dysfunction without impairment in instrumental activities of daily living, with aging being the primary risk factor. Cognitive interventions employ stimulation and training techniques to address this impairment.\n\nObjective: To determine the effect of a cognitive intervention on mild cognitive impairment in older adults with type 2 diabetes mellitus.\n\nMethods: A double-blind, randomized clinical trial involving 102 patients, who will be assigned to either a control group or an intervention group. Data collection will utilize a sociodemographic profile questionnaire and the Montreal Cognitive Assessment (MoCA). The cognitive intervention will be implemented over an average period of two months per subgroup, consisting of eight weekly, 60-minute sessions. Analysis will be conducted using descriptive statistics, and a linear mixed-effects model for repeated measures will be applied to evaluate the intervention's effect.",[67,68,29,69],"Cognitive Intervention","Mild Cognitive Impairment","Diabetes Mellitus",[68,71,72,69],"Cognitive intervention","Elderly adults","NOT_YET_RECRUITING","2026-07-31",{"date":76,"type":43},"2026-08-05",{"date":78,"type":22},"2026-08-03",{"date":80,"type":22},"2026-10-15",{"name":82,"class":83},"Instituto Mexicano del Seguro Social","OTHER_GOV"]